SK9302002A3 - Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3- benzazocines and the use thereof as medicaments - Google Patents

Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3- benzazocines and the use thereof as medicaments Download PDF

Info

Publication number
SK9302002A3
SK9302002A3 SK930-2002A SK9302002A SK9302002A3 SK 9302002 A3 SK9302002 A3 SK 9302002A3 SK 9302002 A SK9302002 A SK 9302002A SK 9302002 A3 SK9302002 A3 SK 9302002A3
Authority
SK
Slovakia
Prior art keywords
methyl
methane
hexahydro
compounds
benzazocine
Prior art date
Application number
SK930-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Adrian Carter
Helmut Ensinger
Wolfram Gaida
Matthias Grauert
Joachim Mierau
Thomas Weiser
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of SK9302002A3 publication Critical patent/SK9302002A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/06—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK930-2002A 1999-11-27 2000-11-21 Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3- benzazocines and the use thereof as medicaments SK9302002A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19957156A DE19957156A1 (de) 1999-11-27 1999-11-27 Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel
PCT/EP2000/011585 WO2001051471A1 (fr) 1999-11-27 2000-11-21 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine substituee et son utilisation comme produit pharmaceutique

Publications (1)

Publication Number Publication Date
SK9302002A3 true SK9302002A3 (en) 2002-11-06

Family

ID=7930562

Family Applications (1)

Application Number Title Priority Date Filing Date
SK930-2002A SK9302002A3 (en) 1999-11-27 2000-11-21 Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3- benzazocines and the use thereof as medicaments

Country Status (32)

Country Link
EP (1) EP1235809B1 (fr)
JP (1) JP2003519687A (fr)
KR (1) KR20020058042A (fr)
CN (1) CN1177825C (fr)
AR (1) AR026586A1 (fr)
AT (1) ATE254108T1 (fr)
AU (1) AU5789701A (fr)
BG (1) BG106682A (fr)
BR (1) BR0015786A (fr)
CA (1) CA2383114C (fr)
CO (1) CO5251469A1 (fr)
CZ (1) CZ20022120A3 (fr)
DE (2) DE19957156A1 (fr)
DK (1) DK1235809T3 (fr)
EA (1) EA005681B1 (fr)
EE (1) EE200200267A (fr)
ES (1) ES2210036T3 (fr)
HR (1) HRP20020460A2 (fr)
HU (1) HUP0204169A3 (fr)
IL (1) IL149607A0 (fr)
MX (1) MXPA02003822A (fr)
NO (1) NO20022457D0 (fr)
NZ (1) NZ519758A (fr)
PL (1) PL355493A1 (fr)
PT (1) PT1235809E (fr)
SK (1) SK9302002A3 (fr)
TR (1) TR200302031T4 (fr)
UA (1) UA72566C2 (fr)
UY (1) UY26448A1 (fr)
WO (1) WO2001051471A1 (fr)
YU (1) YU37902A (fr)
ZA (1) ZA200204056B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6683089B2 (en) 2002-02-02 2004-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg N-allyoxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-ols
DE10204276A1 (de) * 2002-02-02 2003-08-07 Boehringer Ingelheim Pharma N-Allyloxyethyl-1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine und ihre Verwendung als Arzneimittel
EP2917182B1 (fr) * 2012-11-09 2018-01-03 Purdue Pharma LP Analogues de benzomorphane et leur utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121821A1 (de) * 1991-07-02 1993-01-14 Boehringer Ingelheim Kg Neue benzomorphane und ihre verwendung als arzneimittel
US5354758A (en) * 1992-12-16 1994-10-11 Japan Tobacco Inc. Benzomorphans useful as NMDA receptor antagonists
DE19740110A1 (de) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19907874A1 (de) * 1999-02-23 2000-08-24 Boehringer Ingelheim Pharma N-(5-Phenyl-tetrahydrofuranyl)methyl- und N-(6-Phenyl-tetrahydropyranyl)methyl substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
UY26448A1 (es) 2001-06-29
IL149607A0 (en) 2002-11-10
PL355493A1 (en) 2004-05-04
EE200200267A (et) 2003-06-16
AR026586A1 (es) 2003-02-19
DE50004455D1 (de) 2003-12-18
DK1235809T3 (da) 2004-03-15
NO20022457L (no) 2002-05-24
EP1235809B1 (fr) 2003-11-12
UA72566C2 (uk) 2005-03-15
PT1235809E (pt) 2004-04-30
HRP20020460A2 (en) 2003-10-31
WO2001051471A1 (fr) 2001-07-19
KR20020058042A (ko) 2002-07-12
MXPA02003822A (es) 2002-12-13
YU37902A (sh) 2005-07-19
CA2383114C (fr) 2008-06-17
CO5251469A1 (es) 2003-02-28
ATE254108T1 (de) 2003-11-15
JP2003519687A (ja) 2003-06-24
BR0015786A (pt) 2002-08-13
ES2210036T3 (es) 2004-07-01
HUP0204169A2 (hu) 2003-03-28
TR200302031T4 (tr) 2004-01-21
CN1177825C (zh) 2004-12-01
EP1235809A1 (fr) 2002-09-04
HUP0204169A3 (en) 2005-03-29
NO20022457D0 (no) 2002-05-24
CZ20022120A3 (cs) 2002-09-11
AU5789701A (en) 2001-07-24
BG106682A (bg) 2003-01-31
DE19957156A1 (de) 2001-05-31
ZA200204056B (en) 2003-07-30
HK1052176A1 (en) 2003-09-05
EA200200491A1 (ru) 2002-12-26
CN1399630A (zh) 2003-02-26
NZ519758A (en) 2004-05-28
CA2383114A1 (fr) 2001-07-19
EA005681B1 (ru) 2005-04-28

Similar Documents

Publication Publication Date Title
EP0679642B1 (fr) Dérivés hétérocycliques condensés, leur préparation et utilisation
RU2480455C2 (ru) 4-гидроксибензоморфаны
EP0170213B1 (fr) Agents à base de glutarimide ayant des propriétés anxiolytiques et antihypertensives
JP2002529464A (ja) Ｙ５受容体拮抗薬としてのスピロインドリン類
JP2003528046A (ja) フェノキシプロパノールアミン類、それらの製造および治療的使用
JPS61271275A (ja) モルヒナン誘導体
CA2196769C (fr) Derives de benzimidazole presentant une activite dopaminergique
JP2003508528A (ja) ヘテロアリールオキシプロパノールアミン、その製造方法及びそれらを含有する医薬組成物
JP2000512644A (ja) ５―ｈｔ―２ｃ受容体アンタゴニストとして有用なインドリン誘導体
SK9302002A3 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3- benzazocines and the use thereof as medicaments
EP1414457B1 (fr) Dinapsoline chirale
CA1148150A (fr) Phenylmorphanes, produits intermediaires et methode de preparation
US6355652B1 (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and their use as pharmaceutical compositions
WO1990001025A1 (fr) Composes quaternaires d'enamine, procedes de fabrication et leur emploi comme decontracturants musculaires
WO1988001270A1 (fr) Pyridopyrimidinediones
JP2002540108A (ja) ［Ｓ−（Ｒ＊，Ｓ＊）］−β−［［［１−［１−オキソ−３−（４−ピペリジニル）プロピル］−３−ピペリジニル］カルボニル］アミノ］−３−ピリジンプロパン酸及び誘導体を製造する方法
SK14393A3 (en) Sulfonylbenzene substituted derivatives of imidazolylpropene acid
JP5009785B2 (ja) ウレア誘導体、それを含有する医薬組成物およびそれらの医薬用途
US7714129B2 (en) Methods of preparing anhydrous aripiprazole form II
WO2007069050A2 (fr) Procedes pour la preparation d'alfuzosine
KR810001887B1 (ko) 페닐에틸아민류의 제조방법
PL149869B1 (pl) Sposób wytwarzania pochodnych morfinanu